{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:54:51Z","timestamp":1789390491863,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2013,8,15]],"date-time":"2013-08-15T00:00:00Z","timestamp":1376524800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s40261-013-0107-8","type":"journal-article","created":{"date-parts":[[2013,8,14]],"date-time":"2013-08-14T09:59:32Z","timestamp":1376474372000},"page":"707-717","source":"Crossref","is-referenced-by-count":46,"title":["Saxagliptin Add-on Therapy to Insulin With or Without Metformin for Type 2 Diabetes Mellitus: 52-Week Safety and Efficacy"],"prefix":"10.1007","volume":"33","author":[{"given":"Anthony H.","family":"Barnett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Charbonnel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Donovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayyar","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,15]]},"reference":[{"key":"107_CR1","doi-asserted-by":"crossref","unstructured":"DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 2004;88(4):787\u2013835, ix.","DOI":"10.1016\/j.mcna.2004.04.013"},{"issue":"11","key":"107_CR2","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2337\/diabetes.44.11.1249","volume":"44","author":"UK Prospective Diabetes Study Group","year":"1995","unstructured":"UK Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6 years\u2019 therapy of type II diabetes: a progressive disease. Diabetes. 1995;44(11):1249\u201358.","journal-title":"Diabetes"},{"issue":"6","key":"107_CR3","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","volume":"35","author":"SE Inzucchi","year":"2012","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364\u201379.","journal-title":"Diabetes Care"},{"issue":"6","key":"107_CR4","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4158\/EP.15.6.540","volume":"15","author":"HW Rodbard","year":"2009","unstructured":"Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists\/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540\u201359.","journal-title":"Endocr Pract"},{"issue":"11","key":"107_CR5","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1001\/jama.2009.1347","volume":"302","author":"AD Pradhan","year":"2009","unstructured":"Pradhan AD, Everett BM, Cook NR, et al. Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial. JAMA. 2009;302(11):1186\u201394.","journal-title":"JAMA"},{"issue":"8","key":"107_CR6","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/j.1742-1241.2009.02332.x","volume":"64","author":"AH Barnett","year":"2010","unstructured":"Barnett AH, Cradock S, Fisher M, et al. Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes. Int J Clin Pract. 2010;64(8):1121\u20139.","journal-title":"Int J Clin Pract"},{"issue":"2","key":"107_CR7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1463-1326.2010.01317.x","volume":"13","author":"B Charbonnel","year":"2011","unstructured":"Charbonnel B, Cariou B. Pharmacological management of type 2 diabetes: the potential of incretin-based therapies. Diabetes Obes Metab. 2011;13(2):99\u2013117.","journal-title":"Diabetes Obes Metab"},{"issue":"17","key":"107_CR8","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1056\/NEJMoa075392","volume":"357","author":"RR Holman","year":"2007","unstructured":"Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357(17):1716\u201330.","journal-title":"N Engl J Med"},{"issue":"12","key":"107_CR9","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1111\/j.1742-1241.2010.02520.x","volume":"64","author":"J Gordon","year":"2010","unstructured":"Gordon J, Pockett RD, Tetlow AP, et al. A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study. Int J Clin Pract. 2010;64(12):1609\u201318.","journal-title":"Int J Clin Pract"},{"issue":"9","key":"107_CR10","first-page":"528","volume":"110","author":"JS Freeman","year":"2010","unstructured":"Freeman JS. Managing hyperglycemia in patients with type 2 diabetes mellitus: rationale for the use of dipeptidyl peptidase-4 inhibitors in combination with other oral antidiabetic drugs. J Am Osteopath Assoc. 2010;110(9):528\u201337.","journal-title":"J Am Osteopath Assoc"},{"issue":"12 suppl","key":"107_CR11","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.4065\/mcp.2010.0467","volume":"85","author":"JS Freeman","year":"2010","unstructured":"Freeman JS. A physiologic and pharmacological basis for implementation of incretin hormones in the treatment of type 2 diabetes mellitus. Mayo Clin Proc. 2010;85(12 suppl):S5\u201314.","journal-title":"Mayo Clin Proc"},{"key":"107_CR12","unstructured":"ONGLYZA (saxagliptin). Full prescribing information. Princeton, NJ: Bristol-Myers Squibb; 2011."},{"issue":"4","key":"107_CR13","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1185\/03007995.2012.665046","volume":"28","author":"AH Barnett","year":"2012","unstructured":"Barnett AH, Charbonnel B, Donovan M, et al. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin. 2012;28(4):513\u201323.","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"107_CR14","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1007\/s00125-007-0633-0","volume":"50","author":"V Fonseca","year":"2007","unstructured":"Fonseca V, Schweizer A, Albrecht D, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 2007;50(6):1148\u201355.","journal-title":"Diabetologia"},{"issue":"12","key":"107_CR15","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/j.1463-1326.2009.01124.x","volume":"11","author":"J Rosenstock","year":"2009","unstructured":"Rosenstock J, Rendell MS, Gross JL, et al. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab. 2009;11(12):1145\u201352.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"107_CR16","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1463-1326.2009.01173.x","volume":"12","author":"T Vilsboll","year":"2010","unstructured":"Vilsboll T, Rosenstock J, Yki-Jarvinen H, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12(2):167\u201377.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"107_CR17","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/j.1463-1326.2011.01478.x","volume":"13","author":"R Ratner","year":"2011","unstructured":"Ratner R, Wynne A, Nakhle S, et al. Influence of preprandial vs. postprandial insulin glulisine on weight and glycaemic control in patients initiating basal-bolus regimen for type 2 diabetes: a multicenter, randomized, parallel, open-label study (NCT00135096). Diabetes Obes Metab. 2011;13(12):1142\u20138.","journal-title":"Diabetes Obes Metab"},{"issue":"18","key":"107_CR18","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.2146\/ajhp090555","volume":"67","author":"JJ Neumiller","year":"2010","unstructured":"Neumiller JJ, Campbell RK. Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus. Am J Health Syst Pharm. 2010;67(18):1515\u201325.","journal-title":"Am J Health Syst Pharm"},{"issue":"4","key":"107_CR19","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2147\/VHRM.S1707","volume":"4","author":"B Richter","year":"2008","unstructured":"Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag. 2008;4(4):753\u201368.","journal-title":"Vasc Health Risk Manag"},{"issue":"2","key":"107_CR20","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.298.2.194","volume":"298","author":"RE Amori","year":"2007","unstructured":"Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298(2):194\u2013206.","journal-title":"JAMA"},{"issue":"1","key":"107_CR21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3810\/pgm.2011.01.2241","volume":"123","author":"S Jabbour","year":"2011","unstructured":"Jabbour S, Ziring B. Advantages of extended-release metformin in patients with type 2 diabetes mellitus. Postgrad Med. 2011;123(1):15\u201323.","journal-title":"Postgrad Med"},{"issue":"6","key":"107_CR22","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1055\/s-2008-1058090","volume":"40","author":"V Fonseca","year":"2008","unstructured":"Fonseca V, Baron M, Shao Q, et al. Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Horm Metab Res. 2008;40(6):427\u201330.","journal-title":"Horm Metab Res"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-013-0107-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-013-0107-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-013-0107-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,20]],"date-time":"2019-07-20T19:56:59Z","timestamp":1563652619000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-013-0107-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,15]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["107"],"URL":"https:\/\/doi.org\/10.1007\/s40261-013-0107-8","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,15]]}}}